Archives
Patty Maxin's CholangioConnect Experience
As I reflect upon the inception of CholangioConnect, a myriad of emotions flood my being. Unequivocally, I recognize that being…
Monthly Scientific Update – May 2023
APOBEC3-Mediated Mutagenesis in Cholangiocarcinoma Many enzymes are involved in the immune response to viruses and APOBEC3s are a class of…
Celebrating Jan Meyer's Delaware Governor's Outstanding Volunteer Service Award
In this last week of National Volunteer Month, we celebrate Jan Meyer - an exceptional individual who is being recognized…
Monthly Scientific Update – March 2023
Asbestos and Cholangiocarcinoma: A Pilot Study Kelly Butler Asbestos is a mineral-derived carcinogen linked to multiple human cancers. Although asbestos…
Cholangiocarcinoma Awareness Month
February is Cholangiocarcinoma Awareness Month. The Cholangiocarcinoma Foundation (CCF) invites the community to help educate the public about bile duct…
A single arm phase 2 study of Y-90 SIRT in combination with durvalumab (MEDI 4736) and gemcitabine/cisplatin in locally advanced, unresectable or metastatic intrahepatic cholangiocarcinoma
Study Name A single arm phase 2 study of Y-90 SIRT in combination with durvalumab (MEDI 4736) and gemcitabine/cisplatin in locally advanced,…
Bruce Coppock, Former Vice Chair of the Board of Directors of the Cholangiocarcinoma Foundation, Dies at age 71
Cholangiocarcinoma patient Bruce Coppock leaves behind a legacy of leadership benefiting the Cholangiocarcinoma Foundation Bruce Coppock, Vice Chair of the…
Monthly Scientific Update – December 2022
The Oral Microbiome in Cholangiocarcinoma: A Potential Biomarker that Could Promote Early Detection Kelly Butler, Dr. Reham Abdel-Wahab The human…
Giving Tuesday 2022
Thank you to everyone that participated in Giving Tuesday 2022! Donations Last year on Giving Tuesday, people came together to…
Monthly Scientific Update – November 2022 (A recent study investigated the effects of PD-L1 expression on cancer cells and tumor-infiltrating immune cells in intrahepatic cholangiocarcinoma (CCA))
PD-L1 on Tumor-Infiltrating Immune Cells: A Potential Prognostic Biomarker for Cholangiocarcinoma Kelly Butler, Dr. Reham Abdel-Wahab Patients may develop cancer…